Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
Stanislas Pol, Marion Corouge, Anaïs Vallet-Pichard Université Paris Descartes, Liver Department, Assistance Publique Hôpitaux de Paris, Cochin Hospital, French Institute of Health and Medical Research UMS20, Institut Pasteur, Paris, France Abstract: The treatment of h...
Guardado en:
Autores principales: | Pol S, Corouge M, Vallet-Pichard A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3b064159b4154ef999643659d5f8b802 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
por: Mohamed G. Mohamed, et al.
Publicado: (2021) -
Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor PH, et al.
Publicado: (2017) -
Possible acute rejection associated with the use of the new antihepatitis C virus medications
por: Khaled Ar Karkout, et al.
Publicado: (2019) -
Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram V, et al.
Publicado: (2016) -
Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
por: Bernstein D, et al.
Publicado: (2019)